Comparative Pharmacology
Head-to-head clinical analysis: CHOLAC versus XPHOZAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLAC versus XPHOZAH.
CHOLAC vs XPHOZAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic pH. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
XPHOZAH (tenapanor) is a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally in the gastrointestinal tract to inhibit NHE3, reducing sodium and phosphate absorption, leading to decreased serum phosphate levels.
15-30 mL (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 mL/day. For hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
10 mg orally three times daily (TID) with or without food.
None Documented
None Documented
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Terminal elimination half-life is approximately 14 days, supporting monthly subcutaneous dosing for sustained serum phosphate reduction.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Primarily eliminated in feces (approximately 92%) as unchanged drug; renal excretion is negligible (<1%).
Category C
Category C
Laxative
Laxative